Company intelligence / Profile preview
Targeted Therapy Technologies
Irvine, California, United States3tophthalmics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s lead program is episcleral topotecan for pediatric intraocular retinoblastoma. It has received FDA Breakthrough Therapy Designation and is in Phase 2 clinical trials. The technology enables local, non-invasive delivery of small molecules to the eye without penetrating the globe, aiming to improve efficacy and safety over existing treatments
- Therapeutic areas
- OphthalmologyOncology
- Modalities
- Small moleculeDrug delivery device (episcleral drug delivery system)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
U.S. Food and Drug Administration / HHS grant support for clinical trial funding
Beyond the preview
Go deeper on Targeted Therapy Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Targeted Therapy Technologies.